Home » Stocks » Global Blood Therapeutics

Global Blood Therapeutics, Inc. (GBT)

Stock Price: $55.61 USD -3.03 (-5.17%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $56.00 +0.39 (0.70%) Oct 21, 7:59 PM

Stock Price Chart

Key Info

Market Cap 3.41B
Revenue (ttm) 47.73M
Net Income (ttm) -286.39M
Shares Out 61.36M
EPS (ttm) -4.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $55.61
Previous Close $58.64
Change ($) -3.03
Change (%) -5.17%
Day's Open 58.80
Day's Range 55.09 - 58.80
Day's Volume 1,025,259
52-Week Range 39.95 - 87.54

More Stats

Market Cap 3.41B
Enterprise Value 3.02B
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 61.36M
Float 60.25M
EPS (basic) -4.74
EPS (diluted) -4.73
FCF / Share -4.08
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 9.27M
Short Ratio 10.58
Short % of Float 15.38%
Beta 1.74
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 71.50
PB Ratio 7.65
Revenue 47.73M
Operating Income -301.75M
Net Income -286.39M
Free Cash Flow -249.05M
Net Cash 387.45M
Net Cash / Share 6.31
Gross Margin 4.32%
Operating Margin -632.24%
Profit Margin -600.10%
FCF Margin -521.83%
ROA -25.31%
ROE -47.73%
ROIC -62.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (18)

Buy 14
Overweight 1
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(98.98% upside)
Current: $55.61
Target: 110.65
*Average 12-month price target from 17 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit2.06------
Operating Income-290-183-119-83.13-46.39-20.51-15.66
Net Income-267-174-117-82.47-46.36-20.81-18.12
Shares Outstanding58.3251.1542.3233.2112.811.671.23
Earnings Per Share-4.57-3.41-2.76-2.48-3.95-14.20-16.14
Operating Cash Flow-194-135-93.02-67.72-30.89-20.12-14.70
Capital Expenditures-3.42-4.75-3.10-1.35-0.99-0.32-0.94
Free Cash Flow-198-140-96.12-69.08-31.88-20.44-15.64
Cash & Equivalents61248031614714952.21-
Total Debt146------
Net Cash / Debt46648031614714952.21-
Book Value579573319186141-49.33-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Global Blood Therapeutics, Inc.
Country United States
Employees 352
CEO Ted W. Love

Stock Information

Ticker Symbol GBT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GBT


Global Blood Therapeutics, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. The company has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.